Contrasting Daré Bioscience (NASDAQ:DARE) and Pasithea Therapeutics (NASDAQ:KTTA)

Daré Bioscience (NASDAQ:DARE) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.

Institutional & Insider Ownership

6.7% of Daré Bioscience shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 4.0% of Daré Bioscience shares are owned by company insiders. Comparatively, 16.3% of Pasithea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Daré Bioscience and Pasithea Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daré Bioscience	0	2	2	0	2.50
Pasithea Therapeutics	0	0	0	0	0.00

Daré Bioscience currently has a consensus target price of $24.00, indicating a potential upside of 647.66%. Given Daré Bioscience’s stronger consensus rating and higher probable upside, research analysts clearly believe Daré Bioscience is more favorable than Pasithea Therapeutics.

Volatility and Risk

Daré Bioscience has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, Pasithea Therapeutics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500.

Valuation and Earnings

This table compares Daré Bioscience and Pasithea Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daré Bioscience	$2.81 million	9.77	-$30.16 million	($1.12)	-2.86
Pasithea Therapeutics	$20,000.00	176.61	-$15.96 million	N/A	N/A

Pasithea Therapeutics has lower revenue, but higher earnings than Daré Bioscience.

Profitability

This table compares Daré Bioscience and Pasithea Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Daré Bioscience	-253.65%	N/A	-34.72%
Pasithea Therapeutics	N/A	-79.51%	-71.42%

Summary

Daré Bioscience beats Pasithea Therapeutics on 7 of the 12 factors compared between the two stocks.

About Daré Bioscience

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.